NIH-CAP 2007-08 Participating Companies - 11/2007
NIH-CAP 2007-08 Participating Companies
|Acoustic MedSystems, Inc. |Everette C. Burdette |
|Champaign, IL |Tel: 217-239-0900 |
|Industry Sector: Medical Devices |Email: clifb@ |
|Acoustic MedSystems, Inc. (AMS) focuses on the development of minimally invasive interventional methods for treatment, treatment guidance, |
|and delivery monitoring. These are predominately real-time methods for imaging, image processing and therapy delivery guidance. Included are|
|its proprietary ACOUSTXTM technology (Applicators with Controllable Output of Ultrasound for Selective Treatment) for minimally invasive |
|targeted thermal ablation of tumors and other soft-tissue diseases and its spatially-registered image guidance methodologies for treatment |
|delivery and monitoring. The ACOUSTX technology can provide significant benefits and improvements over traditional surgical procedures, as |
|well as over other minimally invasive thermal technologies, and has treatment potential for a wide range of soft-tissues (malignant and |
|benign tumors, other soft tissue disorders) including breast, liver, uterus, prostate, brain, lung, bladder, and colo-rectal diseases. |
|Additionally, the technology can be effective for the treatment of prostate BPH, uterine fibroids, and stress urinary incontinence. The |
|other core technologies of the company are in image registration and real-time intraoperative treatment guidance and monitoring. |
|Advanced Brain Monitoring, Inc. |Mandy Sinning |
|Carlsbad, CA |Tel: 760-720-0099 |
|Industry Sector: Medical Devices |Email: msinning@b- |
|Advanced Brain Monitoring, Inc. (ABM) is the first company to address sleep apnea, memory dysfunction, and alertness monitoring with |
|instrument systems that combine laboratory level accuracy with the portability, ease of use and low cost of consumer electronics. Patients |
|with conditions targeted by ABM’s products total over 110 million people in the US alone, and the vast majority have not been assisted |
|diagnostically. ABM systems make widespread use by physicians, dentists, industrial/transportation companies, and consumers possible. |
|Advanced Circulatory Systems, Inc. |Mike Black |
|Eden Prairie, MN |Tel: 952-947-9551 |
|Industry Sector: Medical Devices |Email: mblack@ |
|Advanced Circulatory Systems is focused on developing and commercializing a sudden cardiac arrest resuscitation system. The platform for |
|this system is a combination of proprietary technologies developed by Advanced Circulatory Systems to increase blood flow during CPR and |
|survival rates for cardiac arrest victims. The goal is to create a cost-effective treatment system through an optimized integration of |
|multiple cardiac arrest-related technologies that will significantly improve cardiac arrest survival rates. |
|AfaSci, Inc. |Xinmin Simon Xie |
|Carlsbad, CA |Tel: 650-784-5658 |
|Industry Sector: Pharmaceuticals |Email: simonxie@ |
|AfaSci, Inc. currently develops a wireless, non-invasive rodent homecage monitoring system for in vivo high-throughput screening (HTS) of |
|drug efficacy and safety, and for behavioral phenotyping of transgenic and knockout mice, through collaborations with Pennsylvania State |
|University, Pennsylvania, The George Washington University, Washington, D.C.), and research institutions (SRI International, CA). We provide|
|products and services in these areas. |
|In the future direction, we will explore contract services on in vivo drug screening and potentially new drug discovery via commercial |
|contracts, collaborations and/or partner with both biotech or pharmaceuticals. |
|AJ Medical Devices, Inc |Robert Arzbaecher |
|Wilmette, IL |Tel: 847-251-5020 |
|Industry Sector: Medical Devices |Email: arzbaecher@iit.edu |
|AJ Medical Devices develops monitoring systems for the high-risk patient that are based on small sensors implanted under the skin that |
|communicate externally via wireless. The first product, CardioAlarm, has an implanted sensor that records a patient’s EKG, automatically |
|detects an abnormal heart rhythm, and transmits an alarm and EKG recording to a 24/7 patient monitoring service, without the encumbrance of |
|electrodes on the skin and wires tethering the patient to a recorder. AJ Medical is seeking capital to complete FDA requirements, begin |
|manufacture and marketing of CardioAlarm, and develop the next in a series of minimally invasive and wireless physiologic monitors. |
|Akaza Research |Cal Collins |
|Cambridge, MA |Tel: 617-621-8585 |
|Industry Sector: Clinical Research |Email: ccollins@ |
|Akaza Research has developed OpenClinica, the leading open source clinical trial data capture and management software platform. Akaza brings|
|Open Source Software (OSS) into the mainstream of the clinical research enterprise by making robust, flexible, standards-based systems |
|accessible for private and public research. Akaza Research provides OpenClinica support, training, and consulting services to its customers |
|worldwide. |
|Allied Innovative Systems, LLC |Simon Bystryak |
|Parsippany, NJ |Tel: 973-919-5707 |
|Industry Sector: Diagnostics |Email: sbystryak@ |
|Allied Innovative Systems (ALLIS) is a research and development company engaged in the development of new technologies in the field of |
|biochemical and biomedical assays and reagents. In particular, we have developed several techniques that increase the sensitivity of |
|enzyme-mediated fundamental analytical assays. This work was supported by NIH SBIR grants. Now, we are in the process of negotiations |
|regarding the commercialization of these technologies with a market leader in biomedical diagnostics. Several novel biochemical assays, such|
|as development of new homogeneous analytical assays based on generation of singlet oxygen and detection of fluorescence polarization, were |
|also developed by ALLIS. |
|Applied Scientific Research |Adrin Gharakhani |
|Santa Ana, CA |Tel: 949-752-7545 |
|Industry Sector: Other |Email: adrin@Applied- |
|Applied Scientific Research (ASR) develops state-of-the-art user-friendly design and analysis software to simulate and visualize |
|thermo-fluid dynamical processes of interest to government and industrial clients in the environmental, bioengineering and medical products |
|sectors, as well as the aerospace, automotive, maritime, and chemical fields. Additionally, ASR provides engineering consulting support to |
|clients in the same fields. At present, ASR has NIH support to develop a highly advanced "virtual test chamber" to investigate blood flow |
|about mechanical heart valves under physiologically realistic flow conditions. Another NIH project supports the development of software for |
|simulating particulate-laden flow, such as flow of platelets and red blood cells in plasma as well as drug particulates or aerosols in |
|carrier fluid streams. |
|Archimage, Inc. |Richard Buday |
|Houston, TX |Tel: 713-523-3425 |
|Industry Sector: Healthcare Media |Email: RBuday@ |
|Archimage is a twenty-four-year-old design studio and winner of over thirty international awards for architecture, television commercials, |
|videogames, websites, and graphic design. The company is wrapping up development of two videogames targeted to preventing obesity and type |
|II diabetes in children. |
|The rising incidence of type II diabetes has reached epidemic proportions, especially among children and young adults. Causes are linked to |
|poor diet and lack of exercise. Diabetes, the leading cause of new blindness and kidney failure, is also the nation’s sixth leading cause of|
|death. The predicted societal and economic impacts are staggering. |
|Videogames are one of the fastest-growing businesses in the entertainment world. Research shows a majority of children and teenagers spend |
|an hour a day playing videogames. The average age videogame player is 33 years old. |
|Archimage believes significant consumer markets exist for videogames that promote healthy lifestyles. |
|Atmospheric Glow Technologies, Inc. |Kimberly Kelly-Wintenberg |
|Knoxville, TN |Tel: 865-777-3776 |
|Industry Sector: Medical Devices |Email: kwintenb@ |
|Atmospheric Glow Technologies, Inc. (AGT) is a science and engineering company developing products based upon patented One Atmosphere |
|Uniform Glow Discharge Plasma (OAUGDP®) technology. The company has assembled an experienced and diverse team of experienced officers and |
|highly trained scientists and engineers committed to technology commercialization. AGT owns two patents and has exclusive rights to eight |
|patents. AGT’s technology uses radio-frequency electric power to generate plasma from air which in turn produces highly oxidative chemical |
|species that can be used beneficially in several application areas. AGT’s plasma doesn’t require special gases or vacuum conditions so it |
|costs less to operate than other plasma technologies. AGT has introduced two products and is working to commercialize other plasma products |
|in the areas of biotechnology, medical device sterilization, air purification, and disinfection of food and other agricultural products. |
|BioFormatix, Inc. |Dariusz Wroblewski |
|Escondido, CA |Tel: 858-248-2884 |
|Industry Sector: Diagnostics |Email: dariusz@ |
|BioFormatix was founded and incorporated in 2004 as a research, product development and service company addressing the needs of biomedical |
|markets. Our technology addresses challenging problems in data collection, data modeling, and software development. |
| |
|The present product development programs, funded by the NIH National Eye Institute, include: |
|* Head mounted apparatus for the visual field testing. |
|* Diagnostic aid software for early detection of glaucoma from the visual field test. |
| |
|Other current interests include: |
|* Computerized personal tools for weight management and diabetes management. |
|* Novel graphical computer interfaces. |
|* Medical diagnostic aid software. |
|* Bioinformatics and novel modeling approaches to analysis of molecular expression data (metabonomic, genomic/transcriptomic, proteomic). |
|BioHesion Inc. |Theo deVos |
|Seattle, WA |Tel: 206-235-3435 |
|Industry Sector: Biotechnology |Email: t.devos@ |
|BioHesion has developed expertise in surface chemistry with an emphasis on derivatizing inert surfaces with biomolecules. We have produced a|
|number of recombinant proteins and peptides which bind gold through high affinity peptide tags, while retaining their biological activity. |
|Based on this, we have developed Goldbinder technology for application in BioSensor and Biomaterials markets. We have developed sensor |
|applications for surface plasmon resonance and colloidal gold to support commercialization of the technology. We are also establishing proof|
|of principle in animal models for Goldbinder technology to enable Biomaterials with robust surface coatings for imaging and drug delivery. |
|Bioptigen, Inc. |Eric Buckland |
|Durham, NC |Tel: 919-314-5500 |
|Industry Sector: Diagnostics |Email: ebuckland@ |
|Bioptigen's pioneering in vivo optical imaging technology allows academic and life science researchers to see pathologies at their earliest |
|stage with unprecedented detail and clarity, across a wide range of subject applications. This sophisticated OCT hardware and software |
|system enables real-time non-invasive imaging of internal tissue microstructure at an unmatched level of precision and depth, and extends |
|the application space to cover a wide range of human and animal subjects. These advances make it possible for researchers to open up new |
|avenues of biological exploration and development, and to foster advances in disease detection and management. |
|Brown & Herbranson Imaging |Bob Austrian |
|Portola Valley, CA |Tel: 415-794-1199 |
|Industry Sector: Clinical Research |Email: baustrian@ |
|eHuman, Inc., and parent company Brown & Herbranson Imaging, are leading providers of 3-D interactive anatomical software applications, |
|services and human datasets for dental, medical and consumer markets. Our core products, already in use within 50% of U.S.-based dental |
|schools, bring the latest volumetric computing, interactive visualization and learning solutions to the spatially complex field of |
|dentistry. Based upon the educational and economic value of our initial products, we are developing the industry’s first Web-based, |
|haptics-enabled surgical simulator and digital curriculum platform, enabling a first-in-class, 21st-century dental pedagogy. Additionally, |
|working with partners including the Stanford School of Medicine, Smithsonian and Max-Planck Institute, our subsidiary is |
|developing the most comprehensive, research-class anatomical imaging, reference and digital learning library for broader health care |
|applications. |
|Caracal, Inc. |DerShung Yang |
|Buffalo Grove, IL |Tel: 847-419-9288 |
|Industry Sector: Healthcare Services |Email: dyang@ |
|Caracal, Inc. is a premier research and development firm specialized in healthcare-related innovative technology solutions to improve |
|patient outcomes, promote patient self-management, improve access to quality care, and reduce healthcare costs. Our solutions are based on |
|multidisciplinary approaches integrating patient-reported outcomes (PRO) research, e-health and telehealth technologies, evidence-based |
|medicine, and patient education and provider training practice. Our solutions are developed with the collaboration from researchers and |
|practitioners at more than a dozen top-rated research and patient care institutions. We are a main contributor to the endeavors integrating |
|PRO solutions developed at the PROMIS Network, an NIH Roadmap project, into mainstream clinical practice. |
|Caring Technologies, Inc. |Ron Oberleitner |
|Boise, ID |Tel: 609-306-9181 |
|Industry Sector: Telemedicine |Email: rono@ |
|Caring Technologies, Inc. delivers a specialty web-based Personal Health Record (PHR) platform which is enhanced by its exclusive worldwide |
|license to a proprietary data capture system called BI Capture™. By delivering these via its popular online autism communication network |
|TalkAutismTM, the Company will revolutionize behavioral medicine treatment and research while providing enriched interaction between |
|individuals with autism and professionals who can be anywhere in the world. Stemming from its traction in the autism category, CT will apply|
|this platform to other pressing health conditions, where the company can leverage this unique hybrid of technology services to facilitate |
|treatment for Alzheimer’s, Parkinson’s, Traumatic Brain Injury, Post Traumatic Stress Disorder, and other costly neurological , |
|neuromuscular and broader chronic illness populations. Ultimately, CT’s technology platform will appeal to the more general health |
|marketplace directly or via sublicense. |
|CellASIC Corporation |Paul Hung |
|San Leandro, CA |Tel: 510-895-1985 |
|Industry Sector: Instrumentation |Email: pauljhung@ |
|CellASIC’s long term vision is to develop microfluidic products to foster the next wave of the life science revolution. In the 20th century,|
|it became possible to isolate and study living components (DNA, proteins, cells) in a laboratory setting, giving rise to the modern |
|pharmaceutical industry. The next revolution in human biology will occur when controlled studies can be replicated in the laboratory that |
|are capable of simulating behaviors of entire living system. The basic concept of CellASIC’s technology is to create microfabricated cell |
|culture environments to improve the quality of laboratory experiments. |
|CFD Research Corporation |Shankar Sundaram |
|Huntsville, AL |Tel: 256-726-4892 |
|Industry Sector: Pharmaceuticals |Email: sxs@ |
|CFD Research Corporation (CFDRC) is the technology leader in advanced engineering solutions (software & hardware, designs and prototypes) |
|for diverse global businesses. CFDRC researches, develops and provides innovative solutions for: |
| |
|* Aerospace and Defense |
|* Biomedical and Life Sciences |
|* Emerging Technologies |
| |
|Our products and services are used by over 500 organizations worldwide. To accelerate global commercialization of matured simulation |
|technologies, in 2004, CFDRC spun off its software products division. Presently, CFDRC has a highly qualified staff of over 90 employees in |
|Huntsville, AL, and active collaborations with over 30 research organizations worldwide. |
| |
|In recognition of our commercialization successes, we have been awarded the prestigious Tibbetts Award twice (latest one in 2006) and have |
|been cited in the success stories of NASA, U.S. Navy, Air Force, DARPA, NIH, NSF, and international magazines. |
|Creatv MicroTech, Inc. |Cha-Mei Tang |
|Potomac, MD |Tel: 301-983-1650 |
|Industry Sector: Diagnostics |Email: cmtang@ |
|Creatv MicroTech, Inc. is developing sensitive biodetection platforms. Creatv’s vision is to become a major supplier of diagnostic tests, |
|analytical tools and reagents for the water, food, environmental, pharmaceutical and medical industries. Creatv achieves innovations through|
|both independent and joint research & development with universities and research laboratories. Creatv also performs development in |
|microfabrication. Creatv manufactures advanced x-ray anti-scatter grids and nuclear collimators to improve medical imaging and received R&D |
|100 Award in 2006 for these products. |
|Danya International, Inc. |David Sherry |
|Silver Spring, MD |Tel: 301-565-2142 |
|Industry Sector: Healthcare Services |Email: dsherry@ |
|Danya International, Inc., designs and implements breakthrough solutions through the creative use of multimedia communications, information |
|technology, and evidence based research. Our mission is to have a social impact on public health and education. As a social impact company, |
|Danya dedicates its resources and talent toward the impact on six social goals: reduce tobacco, alcohol, and other drug use and addiction; |
|improve the quality of comprehensive early childhood education; enhance child and family health; promote mental health education; reduce |
|rates of new HIV infections and other infectious diseases; and promote diversity and inclusion in everything we do. |
|The Multi-Problem Youth (MPY) screening and assessment system is an innovative user friendly tool designed to be rapidly administered to |
|adolescents by primary care and mental health providers. This product offers an engaging use of technology which is unique in the screening |
|and assessment marketplace. |
|DEKK-TEC, Inc. |Lee Roy Morgan |
|New Orleans, LA |Tel: 504-583-6135 |
|Industry Sector: Pharmaceuticals |Email: LRM1579@ |
|DEKK-TEC is a R&D company that has been designing and developing new anticancer drugs and delivery systems since the early 1980s. We have |
|the ability to design, synthesize, test and prepare agents for pre-clinical studies and then finalize their IND applications. Two of our |
|drugs are in Phase II trials (in collaboration with Tigris Pharmaceuticals and Ziopharm Oncology) and a third is ready to enter Phase 1 |
|trials. To date we taken three drugs through IND and into clinical trials. We also have two devices for which we prepared the 510K |
|applications and assisted with their licensing. |
|Dimera, Inc. |R. Kent Hermsmeyer |
|Portland, OR |Tel: 503-295-2775 |
|Industry Sector: Biotechnology |Email: rkh@ |
|Dimera Incorporated is a grant-funded biotech company developing formulations to address angina pectoris and myocardial ischemia in women. |
|Dimera was founded by Dr R Kent Hermsmeyer and investment partners in Portland, Oregon in 1997, based on observations that primate coronary |
|reactivity was suppressed to normal physiological range by low-dose replacement of progesterone, but not medroxyprogesterone acetate. These |
|independently verified studies demonstrate that considerable improvement of coronary function can result from progesterone replacement even |
|with low doses, thus offering a well-tolerated, logical, effective option to current therapies. |
|EduMedia, Inc. |Martin McCarthy, Jr. |
|Evanston, IL |Tel: 847-475-1988 |
|Industry Sector: Healthcare Media |Email: mmcc@northwestern.edu |
|EduMedia is an e-health company specializing in the prevention of disease and the promotion of wellness. We create tailored educational |
|programs for high-risk populations that maintain the health status of users and produce cost-savings for employers. Our current areas of |
|focus are skin cancer, breast cancer, diabetes, low back pain, and depression. Evidence-based behavioral interventions, effective |
|educational strategies, and engaging multimedia content are used to deliver high impact solutions with low unit costs. We seek strategic |
|partnerships with providers of corporate wellness services, forward-looking managed care organizations, high-volume insurers and payers, and|
|established e-health companies. |
|Energetiq Technology, Inc. |Paul Blackborow |
|Woburn, MA |Tel: 781-939-0763 |
|Industry Sector: Diagnostics |Email: pblackborow@ |
|Energetiq is a developer and manufacturer of advanced short wavelength light sources that enable nano-scale structures and products. Used in|
|complex scientific and engineering applications, Energetiq's light products are based on new technology that generates high brightness and |
|high power light in the 1nm to 400nm range with high reliability in a compact package. Energetiq has primarily been developing technology |
|and products for the semiconductor industry. Energetiq is interested in introducing this technology and expertise into the life sciences and|
|medical community. |
|Engineering and Scientific Research Associates |Jafar Vossoughi |
|Olney, MD |Tel: 301-570-9771 |
|Industry Sector: Biotechnology |Email: vossoughi@ |
|The main activity of the company is R&D related to medical products. |
|Genego |Yuri Nikolsky |
|Saint Joseph, MI |Tel: 858-829-6239 |
|Industry Sector: Diagnostics |Email: yuri@ |
|GeneGo is a leading provider of data mining & analysis solutions in systems biology. Our tools and databases help to capture and define the |
|underlying biology behind different types of high-throughput experimental data and understand the effects of small molecule drug compounds |
|in human tissues. We provide systems biology solutions for a full range of applications in life science research and drug development, from |
|pre-clinical discovery and NCE applications to clinical trials, covering all aspects of biology and chemistry. |
|Genopsys |Eric Lietz |
|Soquel, CA |Tel: 831-462-4390 |
|Industry Sector: Biotechnology |Email: ejlietz@ |
|Genopsys is a privately held company developing proprietary diversity technologies to rapidly optimize novel protein products. Genopsys is |
|focused on commercializing molecules that promise to transform the way disease is detected, treated, and managed in cancer and disorders of |
|the central nervous system. |
|HealthCare Interactive, Inc. |John Hobday |
|Edina, MN |Tel: 612-709-7777 |
|Industry Sector: Healthcare Media |Email: jhobday@ |
|HealthCare Interactive is committed to developing the most innovative set of dementia-related training programs available on the market |
|today. To accomplish this, HCI has developed comprehensive Web-based, DVD, and CD-ROM delivered educational programs for patients, |
|caregivers, and professional health workers (doctors, nurses, aides, and individuals involved in the care of the elderly or demented). HCI's|
|software programs are unique, innovative, research-based, and research-validated. Each program has won wide acclaim from family members and |
|professional caregivers alike. |
|Immunomedics, Inc. |Cynthia Sullivan |
|Morris Plains, NJ |Tel: 973 605-8200 |
|Industry Sector: Biotechnology |Email: csullivan@ |
|Immunomedics is a New Jersey-based, publicly-traded (NASDAQ:IMMU) biopharmaceutical company focused on the development of monoclonal |
|antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of |
|proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or |
|conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, |
|we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. |
|Infinite Biomedical Technologies, LLC |Santosh Venkatesha |
|Baltimore, MD |Tel: 410-889-8011 |
|Industry Sector: Medical Devices |Email: santosh@i- |
|Infinite Biomedical Technologies was founded in 1997 and is headquartered in Baltimore, Maryland. IBT is deeply motivated to solve important|
|clinical problems by translating research discoveries into commercially available medical products through device sales and intellectual |
|property licensing. With this ‘bench to bedside’ philosophy, the company focuses on three distinct business lines: global asphyxia, |
|neurocritical care & intraoperative monitoring, and long-term monitoring. IBT’s mission is to become the leading supplier of innovative |
|instrumentation, software, and services for quantitative neurodiagnostics. |
|Infoscitex Corporation |David Montella |
|Waltham, MA |Tel: 781-890-1338 |
|Industry Sector: Medical Devices |Email: dmontella@ |
|IST is a research, development, and engineering firm providing technology solutions and services for defense, life science, and energy & |
|environment customers. IST’s scientists and engineers have an established record of developing technologies from concept to reality and |
|delivering high-value solutions. Core focus areas and services include: Drug Enhancement & Delivery, Electromechanical Systems, Information |
|Technology, Communications, Electronics, Material Processing, Medical Devices, Robotics, Sensors, Research, Development, |
|Commercialization/Transition, Engineering, Systems Analysis/Design, Quality Assurance, Independent Test/Validation, Technology Support, |
|Modeling/Simulation, Technology Assessment, Software Development, and Systems Integration. Infoscitex has 60 employees, and is headquartered|
|in Waltham, MA |
|INFOTECH Soft, Inc. |Patrick Shironoshita |
|Miami, FL |Tel: 305-670-5111 |
|Industry Sector: Healthcare |Email: Patrick.Shironoshita@ |
|INFOTECH Soft, Inc. creates innovative software solutions for healthcare and the life sciences. We continuously expand the state of the art |
|in information technology and computer engineering to create tools that enhance the productivity of health professionals and institutions. |
|Our products focus on the collection, processing and management of clinical trial data, and on the integration of information from diverse |
|and disparate sources into a comprehensive, unified semantic environment. |
|Innovative Biologics, Inc. |Jeff Conroy |
|Herndon, VA |Tel: 703-346-0751 |
|Industry Sector: Biotechnology |Email: jxc@ |
|Innovative Biologics, Inc. is an anti-infective small molecule drug company targeting microbes producing pore-forming toxins, such as MRSA |
|and Hepatitis C. IBI's CycloPlex™ platform identifies compounds which inhibit their action, based on blocking the target pore with molecules|
|having the same symmetry as the pore itself, using ß-cyclodextrin as a scaffold. |
|IBI has been funded with $1.8 million in NIH grants. IBI's initial focus was drug discovery targeting anthrax and other microbes producing |
|pore-forming toxins. IBI has ongoing programs in anthrax and clostridium perfringens. |
|Intrinsic Bioprobes Inc. |Monte Cain |
|Tempe, AZ |Tel: 425-337-2580 |
|Industry Sector: Biotechnology |Email: monte@ |
|Intrinsic Bioprobes Inc. is an Arizona based biotech company that has developed proprietary tools and techniques enabling high-throughput |
|protein analysis and characterization for biomarker and proteomic discovery. Mass Spectrometric Immunoassay (MSIA™ - Tips) are affinity |
|pipettes that selectively isolate proteins out of complex biological fluids. Bioreactive Probes (BRP™) are specialized 96 well plates that |
|modify proteins in a way that is ideal for mass spec analysis. Incorporated into the MASSAY® System and using robotic processes, our system |
|is capable of analyzing up to 2,500 samples per day of proteins obtained directly from biological media. IBI’s integrated resources turn |
|protein analysis into a major strategic advantage by revealing the protein and protein variants associated with disease. These technologies |
|apply directly to drug development, research programs, diagnostics and clinical trial evaluations. |
|Investigen |Heather Koshinsky |
|Hercules, CA |Tel: 510-964-9700 |
|Industry Sector: Diagnostics |Email: ceo@ |
|Investigen is an R&D company dedicated to improve upon existing technologies and develop new Molecular Diagnostic tools. Investigen is |
|developing a proprietary smartDNA™; Molecular Diagnostic platform. While smartDNA can be used in laboratories, its simplicity should make it|
|uniquely able to serve in diagnostic tests that can be used away from a central lab (in peripheral labs, at the POC or at the point of |
|sample collection (POS)). |
|InvoTek, Inc. |Thomas Jakobs |
|Alma, AR |Tel: 479-632-4166 |
|Industry Sector: Other |Email: tjakobs@ |
|InvoTek specializes in technology-based solutions that meet the needs of people with disabilities. InvoTek and our partners have |
|concentrated on developing new ways for people to access computers when standard access methods (mouse and keyboard) are impossible. We have|
|demonstrated the feasibility of four new technologies, including: 1) A 3-D tracking system that enables a person to control the position of |
|a computer cursor using head movement. 2) A very low cost eye-tracking system that enables people to control the position of a computer |
|cursor using eye movement. 3) A dysarthric speech recognition system that, when used in conjunction with word prediction techniques, reduces|
|the number of letters a user must enter by 70% when typing text into a computer. 4) A large-area, light-sensing surface that enabled InvoTek|
|to design eye-safe laser systems for entering text into computers and controlling speech generating devices. |
|ISW Group, Inc. |Monique Spann-Wade |
|St. Louis, MO |Tel: 314-812-8033 |
|Industry Sector: Pharmaceuticals |Email: monique@ |
|ISW Group was founded in 2001 and is a privately held St. Louis-based company. ISW’s mission is to research, develop, and market |
|FDA-approved topical products designed to manage and treat acute and chronic inflammatory skin conditions. ISW has developed a patented |
|technology platform that targets a therapeutically effective dose of drug to relevant dermal targets while minimizing systemic effects. ISW |
|has completed FDA pre-clinical and clinical safety studies for its lead product for the management and treatment of Pseudofolliculitis |
|barbae (PFB), a potentially debilitating dermatologic condition. Additionally, ISW’s technology platform is expected to be useful for a |
|variety of skin conditions including acne keloidalis, boils, dermatitis (eczema), rosacea, and burns. |
|Jambeyang Research |Weiwen Lin |
|Cupertino, CA |Tel: 408-446-0598 |
|Industry Sector: Healthcare |Email: wlin@ |
|Jambeyang Research is a healthcare information technology company that was founded to develop innovative data collection and reporting |
|solutions for the healthcare providers and researchers. Our first product, Breast Imaging Data System, provides streamlined data collection |
|(from patients, office clerks, technologists and radiologists), report generation and distribution, and MQSA support functions that are |
|expected to improve the quality of electronic medical records, patient communication, as well as the overall efficiency of breast imaging |
|exams. This product includes several patentable technologies that can be adopted for other applications. |
|Leo Lens Technology |Praful Doshi |
|San Diego, CA |Tel: 858-335-2873 |
|Industry Sector: Medical Devices |Email: pdoshi@ |
|Leo Lens Technology, founded in 2001, has innovated the next generation of specialty coatings for contact lenses to create additional market|
|of more than billion dollars. Using enabling inkjet printing technology, we have developed contact lenses that provide an exact digital |
|image of an iris with true colors on the lens for cosmetic application &/or antimicrobial coating for healthier eye &/or comfort enhancement|
|for increased use. We provide multiple benefits to the consumer, optometrist and manufacturer. Our growing patent portfolio of more than 20 |
|patents is comprehensive and global. We have FDA approval. We provide multiple benefits to the consumer, optometrist and manufacturer. Leo |
|Lens Technology is looking for a strategic and financial partner for commercialization. |
|LightSpin Technologies, Inc. |Eric Harmon |
|Norfolk, MA |Tel: 508-809-9052 |
|Industry Sector: Diagnostics |Email: harmon@ |
|LightSpin Technologies, Inc. develops the world’s highest performance solid-state photon detectors, achieving single photon sensitivity, |
|high quantum efficiency, wide dynamic range, large photosensitive area and low noise. LightSpin’s photon detectors will supplant fragile, |
|expensive, high voltage photomultiplier tubes with a low cost, low voltage, robust, solid-state solution. These photon detectors are |
|critical components for a wide range of light starved applications, including biomedical instruments, chemical analysis instruments, and PET|
|scanners. |
|Menssana Research, Inc. |Michael Phillips |
|Fort Lee, NJ |Tel: 201-886-7004 |
|Industry Sector: Diagnostics |Email: mphillips@ |
|Menssana Research develops advanced new breath tests for the detection of disease. This includes: |
|a. Hardware for the collection of volatile organic compounds (VOCs) in breath |
|b. Hardware for the analysis of VOCs in breath |
|c. Software: algorithms for interpretation of the results of analysis of VOCs in breath |
|Micron Optics, Inc. |Kevin Hsu |
|Atlanta, GA |Tel: 404-325-0005 |
|Industry Sector: Diagnostics |Email: khsu@ |
|Micron Optics Inc. (MOI), a leading provider of tunable optical technologies, offers a comprehensive portfolio of components and instruments|
|for sensing, telecom, and biotech markets. MOI is a vertically integrated company that conducts applied research, development, |
|manufacturing, marketing, and sales. |
|With over 17 years of dedication, Micron Optics has generated tunable technologies to provide best-in-class optical resolution, accuracy, |
|transmission profile, and dynamic range. The resulting platforms enable a suite of innovative products including tunable filter and fiber |
|grating sensor components, swept laser and optical sensing modules and instruments for use in optical networks and fiber-optic sensing |
|systems. |
|MicroSurfaces, Inc. |Athena Guo |
|Minneapolis, MN |Tel: 612-789-0104 |
|Industry Sector: Diagnostics |Email: athena@ |
|MicroSurfaces, Inc. develops and markets surface technologies for biochips and MEMS. In biochips, we supply functionalized surfaces for |
|biomolecule immobilization on glass slides, coverslips, silicon wafers, ITO, 96 well plate, etc., to research institutes and pharmaceutical |
|companies. We also provide customized coating services for a wide variety of surface functionalities, materials, and devices. The |
|applications for our customers includes, among others, protein/peptide/antibody arrays, biosensor, single molecule spectroscopy, |
|microfluidics, and ELISA. Our coatings feature the lowest background possible (academic & commercial combined). MicroSurfaces is seeking |
|capital investment and partnership to extend product applications in drug discovery and disease diagnostic markets. |
|Mimosa Acoustics, Inc. |Patricia Jeng |
|Champaign, IL |Tel: 217-367-9740 |
|Industry Sector: Medical Devices |Email: klrust@ |
|Mimosa’s main mission and interest is in research, development and manufacturing of preventive inner and middle ear diagnostics. Mimosa |
|prefers to work with strategic partners in the hearing health care industry to market our technology. The technology developed by Mimosa for|
|measuring wide-band acoustic ear-canal input impedance has important implications and applications in the audiological diagnostic and |
|rehabilitative markets. Mimosa plans to develop each of those areas and will provide novel methods to improve the health care in the hearing|
|related areas. |
|Molecular Design International, Inc. |William Purcell |
|Memphis, TN |Tel: 901-529-1919 |
|Industry Sector: Pharmaceuticals |Email: purcell@ |
|Molecular Design International’s (MDI) business model is to discover small molecule therapies and to out-license them to larger |
|biopharmaceutical companies for continued development and commercialization. This approach allows MDI to maintain a highly cost-effective |
|approach to creating innovative treatments for various conditions, while benefiting from the ultimate commercialization of those discoveries|
|through milestone and royalty bearing agreements. |
|Since 1991 MDI has completed six licensing agreements with various biopharmaceutical development companies including Glaxo, Eli Lilly, and |
|J&J. Much of MDI’s success has been made possible through ten SBIR/STTR grants ranging from Phase 1 to Phase 3. |
|Nanotherapeutics, Inc. |James Talton |
|Alachua, FL |Tel: 386-462-9663 |
|Industry Sector: Pharmaceuticals |Email: jtalton@ |
|Nanotherapeutics Inc. is an emerging specialty pharmaceutical company with expertise in the early stage development of pharmaceuticals. The |
|company employs several platform technologies to manipulate and enhance the properties of drugs. These technologies can be employed with new|
|chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to |
|large recombinant macromolecules. |
|Novaflux Technologies |Charles Brumlik |
|Princeton, NJ |Tel: 609-683-0215 |
|Industry Sector: Healthcare Media |Email: brumlik@ |
|Princeton Trade and Technology, Inc. d/b/a Novaflux Technologies is a Princeton, NJ-based, medical device and technology company founded in |
|1988 by Dr. Mohamed E. Labib. To date, the Company has received over $6.0 million from SBIR grants from various government agencies |
|including the National Institutes of Health (NIH), contract research and development (R&D) projects, and licensing. These monies were used |
|to develop the “two-phase flow” technology platform and hemodialyzer and endoescope reprocessors. The Company has 8 US patents on two-phase |
|flow technology, methods, compositions, and devices. |
|Omicia, Inc. |Nomi Harris |
|Emeryville, CA |Tel: 510-595-0800 |
|Industry Sector: Diagnostics |Email: nharris@ |
|Omicia, Inc. is a life sciences company developing technologies and products that translate an individual's unique genetic makeup into |
|clinically actionable information. The company's proprietary system identifies sets of genetic variations that are associated with increased|
|disease risk or differences in drug response. After clinically validating these associations, Omicia combines the complex genetic signatures|
|into a single risk index for each disease or treatment, helping to guide important medical decisions and achieve superior outcomes for each |
|individual. Omicia is a privately held company located in Emeryville, California. |
|Omneuron, Inc. |Christopher deCharms |
|Menlo Park, CA |Tel: 650-585-5303 |
|Industry Sector: Medical Devices |Email: cdecharms@ |
|Omneuron is a life sciences technology company pioneering the use of functional brain imaging for therapeutic intervention. Omneuron is |
|developing methods to translate the exciting progress made in functional MRI brain imaging during the past decade into clinical |
|applications. The Omneuron research team works at a state of the art research facility, with the benefit of access to our own 3T MRI |
|scanner, the support of six NIH grants, exciting technology, and fantastic collaborators. We are currently carrying out clinical trials |
|using real-time functional MRI in two therapeutic areas. |
|Oxford Biomedical Research, Inc. |Denis Callewaert |
|Rochester Hills, MI |Tel: 248-852-8815 |
|Industry Sector: Biotechnology |Email: dcallew@ |
|Oxford Biomedical Research (OBR), founded in 1984, develops and manufactures high quality biological reagents and assay kits for the life |
|science research market. OBR markets over 1,000 products worldwide. OBR’s primary focus is in the development of assays for biomarkers for |
|oxidative stress and chronic inflammation. Several products have been developed with SBIR/STTR funding involving collaborations with |
|internationally recognized scientists. Ongoing research also includes development of improved proteomics methods for the rapid depletion of |
|high abundance serum proteins and for the isolation and quantification of oxidatively-modified proteins, for which multiple patent |
|applications are pending. |
|Perinatronics Medical Systems, Inc. |Thomas Frank |
|Millersville, MD |Tel: 410-987-1305 |
|Industry Sector: Medical Devices |Email: tfrank@ |
|Perinatronics Medical Systems, Inc., is a small high-tech company involved in the hardware and software development of electronic medical |
|instrumentation, including the fields of electrocardiography, fetal heart rate monitoring and magnetic resonance imaging. |
|Photon Migration Technologies |Randall Barbour |
|Glen Head, NY |Tel: 718-270-1286 |
|Industry Sector: Medical Devices |Email: rbarbour@downstate.edu |
|We are pioneering the development of a new economical, portable, and scalable assessment modality that can provide novel insights about |
|integrated body function, early detection of disease states and actions of pharmaceutical agents. Central to this capability is the ability |
|to explore, in real-time, the complex interactions between tissue and its blood supply. To capture this information we have designed a |
|proprietary measurement and analysis platform that can be applied to tissue sizes that range from small animals to man (infants to adults) |
|and equine populations. Our technology is economical, compact, portable and noninvasive. |
|PICS, Inc. |Al Behar |
|Reston, VA |Tel: 703-758-1795 |
|Industry Sector: Pharmaceuticals |Email: albehar@ |
|PICS, Inc. is a health technology company best known for its LifeSign® family of consumer products addressing tobacco cessation (QuitKey®), |
|healthy diet and exercise (DietMate®) and insomnia (SleepKey®). LifeSign® has enjoyed worldwide market acceptance as evidenced by over 1.25 |
|million units sold generating over 100 million dollars in sales. PICS is poised now to greatly save time and money for the research and |
|clinical communities with the introduction of CERTAS®, a researcher - configurable fully integrated EDC system utilizing eDiaries, wireless |
|technology and Interactive Voice Recognition. The uniqueness of CERTAS® will accelerate the design and management of clinical studies. PICS |
|is seeking a partner with the marketing muscle to exploit the large potential for CERTAS® in the CRO and pharmaceutical industries. |
|Point Vista Software |RJ Harrison |
|Oakland, CA |Tel: 510-508-9746 |
|Industry Sector: Diagnostics |Email: rjharrison@ |
|The members of PVS have a long history of success working with each other in various companies and on consulting engagements – the longest |
|dating back 16 years when 2 of the founders met while at Sybase Europe. With vast expertise in the healthcare space, development of |
|electronic medical records systems, databases, smart cards, business applications, and process engineering the PVS is focused on continuing |
|to find ways to improve patient care through the proper use of technology. |
|Potomac Affinity Proteins, LLC |Bonnie Bryan |
|North Potomac, MD |Tel: 301-601-9687 |
|Industry Sector: Biotechnology |Email: potomac_affinity@ |
|Potomac Affinity Proteins, a research and development company, has developed proprietary methods to engineer high-specificity, processing |
|proteases. Potomac has already developed a protease/affinity tag technology for purifying proteins of scientific and pharmaceutical |
|interest. This technology will benefit structural genomics efforts which rely on high-throughput, parallel processing of samples, |
|large-scale purification of pharmaceutical proteins, and rapid production of vaccines in response to naturally-emergent (e.g., avian flu) |
|and intentionally-introduced pathogens (e.g., bio-terrorism). Future development will focus on proteases for use in biosensors and |
|therapeutics. |
|Powerscope, Inc. |Amir Naqwi |
|Minneapolis, MN |Tel: 612-331-4247 |
|Industry Sector: Medical Devices |Email: anaqwi@ |
|Powerscope was founded in 2001 and has the following mission statement: To research, develop, demonstrate and license out products and |
|processes of value to the industry, in particular, medical device industry and pharmaceutical industry. |
|Currently, Powerscope offers a product, FibrSizr(, for in-process real-time measurement of the diameters of polymer and glass fibers. Also a|
|drug nanoparticle generator for pre-clinical studies is developed and would be offered in 2008 through a vendor of pre-clinical research |
|equipment. |
|Powerscope has technical strengths in optical diagnostics, aerosol mechanics and fluid mechanics. Although the company envisions |
|commercialization of newly developed technologies through licensing, Powerscope personnel have background in small-scale manufacturing, as |
|well as sales and marketing. These skills are helpful in introducing new products in the marketplace, before long-term licensing |
|arrangements are made. |
|Precision Bioassay |David Lansky |
|Burlington, VT |Tel: 802-865-0155 |
|Industry Sector: Other |Email: david@ |
|We provide statistical solutions to practical problems in biological assay. We provide consulting services for design, development, |
|analysis, and validation of biological assays. By combining good design of bioassays and validation experiments with our analysis methods |
|(partially based on our proprietary software) we reduce the time needed for development and validation of biological assays while |
|simultaneously improving their precision. This combination reduces the risk of development for biological products, and by improving the |
|precision of biological assays, reduces the routine cost of these assays. |
|Prognosys Biosciences |Charlie Lieu |
|La Jolla, CA |Tel: 858-459-2428 |
|Industry Sector: Biotechnology |Email: clieu@ |
|Prognosys Biosciences is developing innovative assay technologies in the pharmacogenomics and chemical genomic space for life sciences |
|research and development. |
| |
|Our strategy is to: |
|1) Develop and make available novel assays for applications ranging from basic research to clinical diagnostics |
|2) Use them to discover and validate molecular markers that have prognostic value |
|3) Commercialize products and services that are transformative for life sciences applications |
|Protein Discovery, Inc. |Chuck Witkowski |
|Knoxville, TN |Tel: 865-521-7400 |
|Industry Sector: Clinical Research |Email: chuck@ |
|Protein Discovery, Inc. (PDI) is a privately-held life sciences company providing proprietary sample preparation solutions for clinical mass|
|spectrometry. The company is headquartered in Knoxville, TN and employees 12 individuals. PDI has developed three unique sample preparation |
|platforms: (1) imaging mass spectrometry (IMS), (2) specialty reagents for protein research using mass spectrometry, and (3) its |
|MALDIplex(TM) M5 Sample Prep Station. IMS is currently offered as a service and the reagents are sold as products. Both currently produce |
|operational cash flow. MALDIplex is scheduled for product launch in Q1 2008. |
|Rapid Micro Biosystems |Stephen Delity/Don Straus |
|Bedford, MA |Tel: 781-271-1444 |
|Industry Sector: Diagnostics |Email: sdelity@, |
| |dstraus@ |
|The company is developing innovative automated testing platforms that deliver rapid, ultra-sensitive detection of infection and disease |
|markers to address needs in the clinical and biodefense markets. The company has launched its first product, the Growth DirectTM System, |
|which rapidly detects microbiological contamination in pharmaceutical products. With this product launch, the company is reorganizing its |
|personnel and assets into two operating companies. Rapid Micro Biosystems will focus on the Industrial Microbiology market and First Light |
|Biosciences will focus on developing its technology for applications in the clinical and biodefense markets. |
|SANARIA INC. |David Dolberg |
|Rockville, MD |Tel: (510) 685-6405 |
|Industry Sector: Biotechnology |Email: ddolberg@ |
|Sanaria Inc. is the only company in the World dedicated to the development and deployment of a vaccine against Plasmodium falciparum |
|malaria, and the vaccine under development is the only current approach which has a demonstrated efficacy in humans and the potential for > |
|90% prevention of infection. The vaccine comprises live radiation-attenuated P. falciparum parasites. |
|Sanaria has produced its first lot of cGMP product. We have now moved into a 23000 square foot facility which includes a cGMP plant for |
|manufacturing vaccine. We currently have a staff of approximately 37 dedicated individuals including 12 PhDs and/or MDs. |
|SciTech Development, LLC |Earle Holsapple |
|Detroit, MI |Tel: 313-938-5517 |
|Industry Sector: Pharmaceuticals |Email: eth@ |
|SciTech’s mission is to optimize previously shelved anticancer drugs and develop them for specific indicated uses. This optimization and |
|development process resulted in the creation of SciTech's novel drug delivery and pancreatic cancer products. This work has been |
|accomplished by a diverse team of scientists and business leaders formally associated with the Karmanos Cancer Institute. |
|In addition to the drug development work, SciTech has conducted comparative drug toxicity testing studies on bone marrow from several |
|species for various drug development organizations including the NCI. |
|sComm |Jason Curry |
|Independence, MO |Tel: 816-350-7008 |
|Industry Sector: Healthcare |Email: jason@ |
|sComm, Inc develops, engineers, and manufactures the UbiDuo Face to Face Communicator. The UbiDuo enables a deaf/hard of hearing and a |
|hearing individual to communicate with each other face to face without the need of an interpreter. The goal is to allow deaf, hard of |
|hearing, and others with communication barriers to strike up a conversation with hearing people anywhere anytime such in professional or |
|social communication situations. The UbiDuo changes the landscape for face to face communication. The development of the UbiDuo was funded |
|by a grant from the National Institute on Deafness and Other Communication Disorders with the National Institute of Health. sComm was |
|founded by father and son out of frustration when they both were trying to converse with each other over breakfast on Saturday morning 5 |
|years ago. |
|SVision, LLC |James Lee |
|Bellevue, WA |Tel: 425-450-1014 |
|Industry Sector: Instrumentation |Email: jamesl@ |
|SVision LLC provides the next-generation image-based decision technology and products that solve the most difficult challenges in industrial|
|inspection, measurement and alignment, cell and tissue analysis, dynamic image bioinformatics, and data mining applications. SVision is a |
|technological innovator with 29 issued, 1 allowed and 16 pending US patents. Since 1999, SVision has been pioneering the use of machine |
|learning technology in a broad range of practical image recognition applications. SVision develops and markets the next generation |
|microscopy image analysis software, SVCell, whose development is partially funded by the National Institute of Health (NIH) under multiple |
|Small Business Innovative Research programs. |
|Tanglewood Research, Inc. |William Hansen |
|Greensboro, NC |Tel: 336-662-0090 |
|Industry Sector: Healthcare |Email: billhansen@ |
|Tanglewood Research, Inc. has as its mission to translate behavioral technology into practical applications in the area of health promotion.|
|The company focuses on the develop of products and services in three interdependent areas: effective programming to promote wellness and the|
|prevention of risky behaviors, tools for conducting research and evaluation to assess the effectiveness of health and wellness interventions|
|(particularly for adolescents), and the professional development of health promotion and prevention service providers. |
|TDA Research, Inc. |Steven Dietz |
|Wheat Ridge, CO |Tel: 303-940-2312 |
|Industry Sector: Pharmaceuticals |Email: sdietz@ |
|TDA Research, Inc. develops advanced materials and chemical processes that it can either manufacture or license. TDA has been in operation |
|for 20 years, and employs 70 people, nearly all with degrees in either chemistry or engineering. In the past four years we have licensed and|
|commercialized two major processes, the multi-ton manufacture of fullerenes and a partial oxidation process that removes sulfur from natural|
|gas, both of which have multi-million dollar per year sales. Last year, annual sales by our partners of products developed at TDA with SBIR |
|funding exceeded $4.5 million. |
|TechniScan, Inc. |David Robinson |
|Salt Lake City, UT |Tel: 801-521-0444 |
|Industry Sector: Diagnostics |Email: drobinson@ |
|TechniScan Medical Systems (TMS) is a privately held medical device company engaged in the development and commercialization of a |
|revolutionary ultrasound imaging system, UltraSound CTTM (WBUTM), to aid in the diagnosis of breast cancer. TMS’ imaging system is designed |
|to provide physicians with a new, non-invasive, diagnostic imaging tool that will provide detailed information about the anatomy (i.e. |
|physical structures within the breast) and pathology (i.e. bulk tissue properties). The system is intended to be used as an adjunct to |
|mammography to aid physicians in diagnosing breast cancer by helping to differentiate normal or benign from malignant tissue in the breast. |
|The Virtual Reality Medical Center |Mark Wiederhold |
|San Diego, CA |Tel: 858-642-0267 |
|Industry Sector: Medical Devices |Email: mwiederhold@ |
|The Virtual Reality Medical Center, with clinics in San Diego, Los Angeles, and Palo Alto is a world leader in applying virtual reality |
|technology in combination with physiological monitoring and feedback. VRMC software/hardware technology is used for: |
|*Evaluation and treatment of patients with anxiety disorders |
|*Distraction for patients with acute or chronic pain |
|*Treatment of returning veterans with posttraumatic stress disorder |
|*Cognitive rehabilitation of patients with traumatic brain injury |
|Clinical studies, both published and in progress, show that this technology is safe, effective, and cost effective, because VR can speed the|
|attainment of desired outcomes. |
|Transtimulation Research Inc. |Jiande Chen |
|Oklahoma City, OK |Tel: 832-640-8111 |
|Industry Sector: Medical Devices |Email: jiandechen@ |
|Transtimulation Research Inc. is a startup company based in Oklahoma City. The mission of the company is to develop novel methods for the |
|diagnosis and treatment of digestive disorders and obesity. Currently, the company has been working on electrical stimulator for the |
|treatment of obesity. Particularly the company has a number filed patents on new methodologies for the treatment of obesity using electrical|
|stimulation of the gut. In addition, the company is also working new methods of electrical stimulation for the treatment of diabetes and |
|functional gastrointestinal disorders. |
|TSRL, Inc. |Elke Lipka |
|Ann Arbor, MI |Tel: 734-663-4233 |
|Industry Sector: Biotechnology |Email: elipka@ |
|Therapeutic Systems Research Laboratories (TSRL), Inc. is a pharmaceutical research firm, specializing in oral drug delivery, drug transport|
|and biopharmaceutical properties of drug delivery. We have developed a variety of formulations for improved oral drug delivery, including |
|pulsatile drug release technology, the Programmable Oral Release Technology (PORT) Capsule, and water insoluble drug technology. TSRL, Inc. |
|developed PK simulation software for the pharmaceutical and biotechnology industries. More recently we have focused on prodrug strategies as|
|well as the development of a carrier technology, the Bile Acid Conjugate (BAC), which enable oral delivery of highly polar and/or charged |
|drug candidates. |
|Urovalve, Inc. |Harvey Homan |
|Newark, NJ |Tel: 973-596-1350 |
|Industry Sector: Medical Devices |Email: harveydhoman@ |
|Urovalve is an early stage company whose mission is to design, develop, and commercialize superior medical devices that address problems |
|with urinary flow and control. Urinary retention can be caused by neuromuscular problems that impair the ability to relax the urinary |
|sphincters or by physical obstructions to the urethra, and affects up to 6 million men. Urovalve's innovative intraurethral valved-catheter |
|is designed to return control of bladder emptying to the user, therefore improving quality of life and reducing urinary tract infection |
|risk. The commercialization of this Surinate® device will launch Urovalve into the urology segment of the medical device industry. |
|VPDiagnostics, Inc. |Hui Hu |
|Seattle, WA |Tel: 206-428-6160 |
|Industry Sector: Diagnostics |Email: hui@ |
|VPDiagnostics, Inc. develops software products that identify, analyze and visualize the dangerous vulnerable plaque responsible for most |
|strokes. Leveraging patented technologies and collaboration with our university research partners, we have a unique product that employs MRI|
|for imaging and analyzing atherosclerosis in vivo; and that has been undergone extensive pathological validation. Our product is the only |
|one specialized in plaque characterization within the arterial wall with the carotid arteries as the initial area of application. |
|Our mission is to improve stroke prevention by providing a critical tool to better estimate the risks of most strokes. VPDiagnostics is |
|achieving its goal through an experienced team, innovative technologies, application focused design, quality execution, and clinical and |
|industrial partnership. |
|Ximerex, Inc. |William Beschorner |
|Blair, NE |Tel: 402-426-0660 |
|Industry Sector: Biotechnology |Email: beschorner@ |
|Ximerex, Inc. proposes to satisfy a major unmet need in organ and tissue transplantation. Using the tools of hematopoietic stem cells, cell |
|therapy, and xenotransplantation, the Company has developed proprietary technology to transplant tissues from pigs without the need for |
|drugs to prevent rejection. |
|Hematopoietic stem cells from the patient are processed and grown within fetal pigs. The human T regulatory cells from the injected pig are |
|later isolated and transferred back into the patient, conveying specific tolerance to the donor pig. Subsequently, pig tissue is |
|transplanted into the patient. The technology is useful for type 1 diabetes, heart failure, etc. |
|XL Sci-Tech, Inc. |Y. Benjamin Peng |
|Richland, WA |Tel: 509-531-3558 |
|Industry Sector: Medical Devices |Email: BenPeng@ |
|XL Sci-Tech develops and produces timed bioabsorbable radioactive devices for the treatment of soft tissue cancers. It has developed a |
|protectable timed-bioabsorbable biomaterial platform along with a proprietary micro-fabrication process for radioactive materials. The first|
|application is the creation of BetaSpheres®, which consists of timed-bioabsorbable Y-90 microspheres for treatment of inoperable |
|hepatocellular carcinoma (HCC) and metastatic liver cancer. The application of timed-bioabsorbable delivery of Pd-103 for prostate cancer |
|and other soft tissue cancers expands the scope of brachytherapy and makes timed-bioabsorbable matrix a true encapsulation and delivery |
|platform for gamma emitters, as well as beta emitters. Timed-bioabsorbable brachytherapy seeds advance the state-of-the-art and offer |
|critical new treatment options that are no possible with the current seed technologies. |
|Zylon Medical Devices |Jack Klein |
|Chestnut Ridge, NY |Tel: 845-425-9469 |
|Industry Sector: Medical Devices |Email: support@ |
|Zylon Corporation is located at 600 Chestnut Ridge Rd., Chestnut Ridge, NY 10977 in 2500 square feet of laboratory and office facilities. |
|Core competency involves polymer science as applied to medical devices and clinical procedures related to it. Zylon originally was formed to|
|provide expertise related to polymers and medical products made from polymers. Zylon has a current specialization in medical balloon |
|catheters and related devices. |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- nih cap company descriptions 2008 09
- advanced technological education 1996 awards and activities
- price list gsa advantage
- archived 2006 science and technology engineering
- press release acd labs 8 20 2003 agilent
- gsa advantage
- nih cap 2007 08 participating companies 11 2007
- nih cap 2005 06 participating companies 11 2007
Related searches
- healthways participating fitness centers
- silversneakers participating locations
- zelle participating banks
- work number participating employer list
- the work number participating employers
- small cap tech companies 2019
- teach grant program participating schools
- 08 f150 firing order
- fafsa participating schools
- 7mm 08 bullet drop
- large cap companies in india
- best 7mm 08 deer bullet